Millions Lose GLP‑1 Coverage
- Analysis cited by STLPR says 12 million people lost coverage for Zepbound over the past year, and the same number lost coverage for Wegovy. - Those coverage losses affect two major GLP-1 weight-loss drugs simultaneously. - Patients and prescribers face growing insurance restrictions even as demand for GLP-1s rises, forcing treatment pivots (stlpr.org).
Millions of Americans lost insurance coverage over the past year for Wegovy and Zepbound, the two biggest brand-name weight-loss injections. (goodrx.com) GoodRx said 12 million people lost commercial coverage for Wegovy from 2025 to 2026, and another 12 million lost coverage for Zepbound. Its analysis used formulary data from Managed Markets Insight & Technology, or MMIT, covering more than 190 million people. (goodrx.com; tspr.org) The same analysis found more than 41 million people now have no commercial coverage for Wegovy and more than 109 million have no commercial coverage for Zepbound. Among people who still have coverage for weight-loss versions of glucagon-like peptide-1 drugs, more than 88% face hurdles such as prior authorization or step therapy. (goodrx.com) Glucagon-like peptide-1 drugs mimic gut hormones that reduce appetite and slow digestion, and the obesity brands in this market are Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Wegovy is approved for chronic weight management and, in some adults with cardiovascular disease and overweight or obesity, to reduce the risk of heart attack and stroke. (novomedlink.com) The coverage pullback is landing on patients who had already started treatment and were paying standard copays. NPR reported that Meghan Lena, a Massachusetts special education teacher, paid $30 a month for Zepbound, lost 50 pounds in a year, then had to switch when CVS Caremark dropped Zepbound in July and her employer plan later dropped Wegovy in October. (tspr.org) Without insurance, patients can be pushed into manufacturer cash-pay programs, discount cards, or compounded alternatives. Wegovy’s current direct savings page says eligible commercially insured patients may pay as little as $25 a month, while self-pay pricing starts at $149 a month for some doses and rises later in 2026; Lilly’s Zepbound site directs uninsured or uncovered patients to separate self-pay savings options. (wegovy.com; zepbound.lilly.com) Drugmakers say coverage varies by plan and can change month to month. Novo Nordisk’s formulary page says its coverage tool is only a guide and “not a guarantee of coverage,” while Lilly tells patients to confirm details directly with their insurer. (novomedlink.com; zepbound.lilly.com) Insurers and pharmacy benefit managers have been tightening access even as demand stays high. NPR reported on April 15 that plans were dropping obesity-drug coverage or adding new restrictions, extending a pattern that has made access “spotty at best” for years. (wwno.org) For patients already taking these medicines, the practical question is often no longer which drug works best. It is which drug their plan will still cover next month. (tspr.org; goodrx.com)
